Abstract
Purpose
Campylobacter is a frequent cause of enteric infections with common antimicrobial resistance issues. The most recent reports of campylobacteriosis in Italy include data from 2013 to 2016. We aimed to provide national epidemiological and microbiological data on human Campylobacter infections in Italy during the period 2017–2021.
Methods
Data was collected from 19 Hospitals in 13 Italian Regions. Bacterial identification was performed by mass spectrometry. Antibiograms were determined with Etest or Kirby-Bauer (EUCAST criteria).
Results
In total, 5419 isolations of Campylobacter spp. were performed. The most common species were C. jejuni (n = 4535, 83.7%), followed by C. coli (n = 732, 13.5%) and C. fetus (n = 34, 0.6%). The mean age of patients was 34.61 years and 57.1% were males. Outpatients accounted for 54% of the cases detected. Campylobacter were isolated from faeces in 97.3% of cases and in 2.7% from blood. C. fetus was mostly isolated from blood (88.2% of cases). We tested for antimicrobial susceptibility 4627 isolates (85.4%). Resistance to ciprofloxacin and tetracyclines was 75.5% and 54.8%, respectively; resistance to erythromycin was 4.8%; clarithromycin 2% and azithromycin 2%. 50% of C. jejuni and C. coli were resistant to ≥ 2 antibiotics. Over the study period, resistance to ciprofloxacin and tetracyclines significantly decreased (p < 0.005), while resistance to macrolides remained stable.
Conclusion
Campylobacter resistance to fluoroquinolones and tetracyclines in Italy is decreasing but is still high, while macrolides retain good activity.
Similar content being viewed by others
Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
References:
Campylobacter FC (2015) Clin Lab Med 35(2):289–298. https://doi.org/10.1016/j.cll.2015.03.001
Rukambile E, Sintchenko V, Muscatello G, Kock R, Alders R (2019) Infection, colonization and shedding of Campylobacter and Salmonella in animals and their contribution to human disease: A review. Zoonoses Public Health 66(6):562–578. https://doi.org/10.1111/zph.12611
Costa D, Iraola G (2019) Pathogenomics of Emerging Species. Clin Microbiol Rev. 32(4). https://doi.org/10.1128/CMR.00072-18
Kaakoush NO, Castaño-Rodríguez N, Mitchell HM, Man SM (2015) Global Epidemiology of Campylobacter Infection. Clin Microbiol Rev 28(3):687–720. https://doi.org/10.1128/CMR.00006-15
European Food Safety Authority, European Centre for Disease Prevention and Control (2022) The European Union One Health 2021 Zoonoses Report. EFSA J 20(12):e07666. https://doi.org/10.2903/j.efsa.2022.7666
Shane AL, Mody RK, Crump JA, Tarr PI, Steiner TS, Kotloff K et al (2017) 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis 65(12):1963–1973. https://doi.org/10.1093/cid/cix959
Bennett JE, Dolin R, Blaser MJ (2019) Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases: 2-Volume Set [Internet]. Elsevier 216:2650–2659
Qin X, Wang X, Shen Z (2023) The rise of antibiotic resistance in Campylobacter. Curr Opin Gastroenterol 39(1):9–15. https://doi.org/10.1097/MOG.0000000000000901
WHO publishes list of bacteria for which new antibiotics are urgently needed [Internet]. [cited 2023 Aug 13]. Available from: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
European Centre for Disease Prevention and Control. Campylobacteriosis. In: ECDC. Annual epidemiological report for 2021. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/campylobacteriosis-annual-epidemiological-report-2021.pdf
García-Fernández A, Dionisi AM, Arena S, Iglesias-Torrens Y, Carattoli A, Luzzi I (2018) Human Campylobacteriosis in Italy: Emergence of Multi-Drug Resistance to Ciprofloxacin, Tetracycline, and Erythromycin. Front Microbiol 22(9):1906. https://doi.org/10.3389/fmicb.2018.01906
Conesa A, Garofolo G, Di Pasquale A, Cammà C. Monitoring AMR in Campylobacter jejuni from Italy in the last 10 years (2011–2021): Microbiological and WGS data risk assessment. EFSA Journal. 2022 May [cited 2023 Jul 10];20(Suppl 1). 10.2903%2Fj.efsa.2022.e200406
ESCMID-European Society of Clinical Microbiology and Infectious Diseases. Eucast: Clinical breakpoints and dosing of antibiotics [Internet]. [cited 2023 Aug 13]. Available from: https://www.eucast.org/clinical_breakpoints
Bessède E, Lehours P, Labadi L, Bakiri S, Mégraud F (2014) Comparison of characteristics of patients infected by Campylobacter jejuni, Campylobacter coli, and Campylobacter fetus. J Clin Microbiol 52(1):328–330. https://doi.org/10.1128/jcm.03029-13
Wagenaar JA, van Bergen MA, Blaser MJ, Tauxe RV, Newell DG, van Putten JP (2014) Campylobacter fetus infections in humans: exposure and disease. Clin Infect Dis 58(11):1579–1586. https://doi.org/10.1093/cid/ciu085
Schmutz C, Mäusezahl D, Jost M, Baumgartner A, Mäusezahl-Feuz M. Inverse trends of Campylobacter and Salmonella in Swiss surveillance data, 1988–2013. Euro Surveill. 2016;21(6): 30130. https://doi.org/10.2807/1560-7917.ES.2016.21.6.30130
Dias SP, Brouwer MC, van de Beek D (2022) Sex and Gender Differences in Bacterial Infections. Infect Immun 90(10):e0028322. https://doi.org/10.1128/iai.00283-22
McNeil CJ, Kirkcaldy RD, Workowski K (2022) Enteric Infections in Men Who Have Sex With Men. Clin Infect Dis 74(Suppl_2):S169–S178. https://doi.org/10.1093/cid/ciac061
Green MS, Schwartz N, Peer V (2020) Sex differences in campylobacteriosis incidence rates at different ages - a seven country, multi-year, meta-analysis. A potential mechanism for the infection. BMC Infect Dis 20(1):625. https://doi.org/10.1186/s12879-020-05351-6
Pacanowski J, Lalande V, Lacombe K, Boudraa C, Lesprit P, Legrand P et al (2008) Campylobacter bacteremia: clinical features and factors associated with fatal outcome. Clin Infect Dis 47(6):790–796. https://doi.org/10.1086/591530
Otsuka Y, Hagiya H, Takahashi M, Fukushima S, Maeda R, Sunada N et al (2023) Clinical characteristics of Campylobacter bacteremia: a multicenter retrospective study. Sci Rep 13(1):647. https://doi.org/10.1038/s41598-022-27330-4
Tinévez C, Velardo F, Ranc AG, Dubois D, Pailhoriès H, Codde C et al (2022) Retrospective Multicentric Study on Campylobacter spp. Bacteremia in France: The Campylobacteremia Study. Clin Infect Dis 75(4):702–9. https://doi.org/10.1093/cid/ciab983
Liu YH, Yamazaki W, Huang YT, Liao CH, Sheng WH, Hsueh PR (2019) Clinical and microbiological characteristics of patients with bacteremia caused by Campylobacter species with an emphasis on the subspecies of C. fetus. J Microbiol Immunol Infect. 52(1):122–131. https://doi.org/10.1016/j.jmii.2017.07.009
L’uso degli antibiotici in Italia. Rapporto Nazionale 2021. Agenzia Italiana del Farmaco. https://www.aifa.gov.it/documents/20142/1853258/Rapporto_Antibiotici_2021.pdf [accessed on Jan. 31, 2024]
Sales of veterinary antimicrobial agents in 31 European countries in 2022. European Medicines Agency. https://www.ema.europa.eu/system/files/documents/other/italy_pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf [accessed on Jan. 31, 2024]
Rousou X, Furuya-Kanamori L, Kostoulas P, Doi SAR (2023) Diagnostic accuracy of multiplex nucleic acid amplification tests for Campylobacter infection: a systematic review and meta-analysis. Pathog Glob Health 117(3):259–272. https://doi.org/10.1080/20477724.2022.2097830
Funding
This study received no external funding.
Author information
Authors and Affiliations
Contributions
SDB and LP conceived the idea of and designed the study with VZ; SA, SA, RA, MB, AB, GB, MB, GC, DC, AC, NC, EC, CC, GC, AC, VC, VC, MDS, SD, BF, EG, FG, NM, AEM, AM, DM, RM, CM, AM, GM, AM, GN, EP, EMP, SP, MS, AS, DT and CV contributed to investigation and data collection; GS, RP and VZ analysed the data; VZ wrote the first draft; SDB, LP, VZ, RP, AGF, LV, RMLR, CF and GS contributed to the interpretation of the data, writing and reviewing of the first draft of the manuscript. All authors reviewed and commented on subsequent versions of the manuscript. All authors approved the submitted version of the manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
The planning, conduct and reporting of this study was in line with the Declaration of Helsinki. The study was approved by the Trieste University Ethical Committee (n°V132_2806_23). Consent to participate was assessed according to the Ethical Committee.
Consent to publish
Not applicable.
Competing Interests
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zerbato, V., Di Bella, S., Pol, R. et al. Human Campylobacter spp. infections in Italy. Eur J Clin Microbiol Infect Dis (2024). https://doi.org/10.1007/s10096-024-04803-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10096-024-04803-0